Clinical Trials

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07232602 2026-04-13

MK-3475-04D

55 enrolled

Urinary Bladder Neoplasms

NCT07421700 2026-04-07

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

132 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03288545 2026-03-24

EV-103

Phase 1/2 Terminated

348 enrolled 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT05614739 2026-03-23

FORAGER-1

Phase 1 Recruiting

535 enrolled

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT06470282 2026-02-18

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

47 enrolled

Urinary Bladder Neoplasms

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

75 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

808 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

272 enrolled

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06305767 2026-01-13

INTerpath-005

230 enrolled

608 enrolled 22 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05656235 2026-01-08

Renal Retention in High Grade Upper Tract Urothelial Cancer

20 enrolled

Urinary Bladder Neoplasms

NCT07087860 2025-12-09

RECIPE-B1

70 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05014139 2025-11-20

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Terminated

37 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT06394570 2025-09-15

STAR-EV

19 enrolled

Urinary Bladder Neoplasms

NCT05879653 2025-08-29

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

30 enrolled

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03924895 2025-08-28

KEYNOTE-905

595 enrolled 3 FDA

Urinary Bladder Neoplasms

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

25 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05524545 2025-07-25

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Phase 1 Completed

36 enrolled

219 enrolled 32 charts 4 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03219333 2024-08-27

EV-201

Phase 2 Completed